> Trellis Blog <

Articles & insights to keep you updated on our latest developments

Articles & insights to keep you updated on our latest developments

Stay up-to-date with our latest platform developments.

Navigating Eylea (Aflibercept) Prior Authorization Policies Across Major U.S. Payers

Navigating Eylea (Aflibercept) Prior Authorization Policies Across Major U.S. Payers

Eylea (aflibercept) is a leading anti-VEGF (vascular endothelial growth factor) therapy indicated for retinal conditions such as neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR), …

Eylea (aflibercept) is a leading anti-VEGF (vascular endothelial growth factor) therapy indicated for retinal conditions such as neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR), …

Read more

> Start today <

Let us take care of the MESS(y) data

Let us take care of the MESS(y) data

Click below to get access to our product and explore how Trellis can help you and your organization unlock new insights!

Book demo

Book demo

Book demo

2025 Trellis. All rights reserved.

2025 Trellis. All rights reserved.